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GUEST EDITORIAL
The role of surgery in metastatic testicular germ cell tumours
(GCT)
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Dept of Medical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Germ cell tumour (GCT) has now become accepted as a term which includes a wide range of
pathological entities, including seminoma, teratoma, choriocarcinoma, yolk sac tumour and embryonal
carcinoma. From the point of view of management, there are two subgroups, seminoma and the rest
(these have been called non-seminomatous germ cell tumours). Although the testis is the commonest site
for GCT, primary tumours can also occur in the ovaries, retroperitoneum, mediastinum and central
nervous system. The anatomical location of germ cell tumour other than the testis dictates different
surgical approaches. However, the overall managements of germ cell tumours at all sites now have many
common aspects. Provided that the diagnosis is made before there is widespread disease, long-term
survival should exceed 80% provided management is appropriate.
The major metastatic sites for testicular GCT are para-aortic lymph nodes, mediastinal lymph nodes
and the lungs. Since all of these are amenable to surgery, the place of resection in the management of
disease at each site has to be considered as does, in particular, the timing of chemotherapy and surgery.
The availability of a number of investigations has altered our approach to evaluation of the role of
surgery. CT scanning has dramatically improved localisation of tumours in the central nervous system,
lungs, mediastinum and retroperitoneum. However, our experience is that ultrasound is complementary
to CT scanning in the abdomen. It is usually superior in localising hepatic metastases and can identify
para-aortic nodes that are closely adjacent to the main vessels, which on CT scan are difficult to
distinguish from the vessels themselves. Serum markers, human chorionic gonadotrophin (hCG) alpha
fetoprotein (AFP) and lactate dehydrogenase (LDH) have a central role in the diagnosis, staging and
follow-up of non-seminoma.
After initial diagnosis of non-seminoma by inguinal orchidectomy and careful staging tests, many
centres in the UK now institute meticulous follow-up but offer no further treatment unless metastatic
disease is or subsequently becomes apparent. In our experience, 25% of patients will relapse but can be
salvaged by chemotherapy. This 'surveillance' policy, which is widely used in the United Kingdom, is in
contrast to the approach in the United States, where para-aortic nodal lymphadenectomy has been
widely used for many years. The argument in favour of para-aortic nodal lymphadenectomy in patients
with testicular GCT has been that this gives a pathological staging. It is also known that patients with
early metastatic disease in their para-aortic nodes have an approximately 60% chance of not requiring
additional treatment following lymphadenectomy (Pizzocaro et al., 1984). However, patients with large
volume para-aortic disease (greater than 5cm diameter) clearly require chemotherapy in addition. A
recent randomised study from Williams et al. (1987) has addressed the question of whether patients with
confirmed pathological para-aortic nodal involvement should receive early chemotherapy or be followed
up so that only those relapsing received chemotherapy. The results in both groups were similarly good.
The problem with these studies is that, although the survival results are excellent, retroperitoneal nodal
dissection carries a degree of morbidity and in particular some patients become infertile because of
failure of ejaculation. In Europe, few centres follow this approach because of these sequelae and
comparable results can be obtained without using surgery as a staging procedure for the para-aortic
nodes.
The chemotherapy of GCT has been transformed over the past decade with the introduction of two
new drugs, cisplatinum (Einhorn & Donohue, 1977) and etoposide (Newlands & Bagshawe, 1977;
Newlands et al., 1986). Before this the majority of patients with metastatic GCT responded dramatically
to chemotherapy but in 90% of cases drug resistance ensued and most patients died within a matter of
months. During this decade, experience of integrating these new agents into the chemotherapy in GCT
has evolved. It is probably necessary for patients with metastatic disease to receive a minimum of
300mgm-2 of cisplatinum over a relatively short period of time to maximise the remission rate. Also,
cisplatinum needs to be used in combination. Initially, Einhorn and colleagues used it with vinblastine
and bleomycin. After some delay, this group recognised that etoposide should be integrated into the
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primary chemotherapy, and the combination of cisplatinum, etoposide and bleomycin has produced
superior results in patients with large volume metastatic disease (Williams et al., 1987). The addition of
other active agents such as methotrexate, vincristine, actinomycin D and cyclophosphamide probably
improves the complete remission rate still further in patients with the most advanced disease (Hitchins et
al., 1989). It is the ability of modern chemotherapy to sterilise even large volumes of metastatic disease
which has altered the role of surgery.
In patients with a metastatic pure seminoma with no AFP and minimal elevation of hCG the
management is still by radiotherapy (provided the para-aortic nodal mass is not sufficiently large to
require chemotherapy to reduce it in order to minimise radiation to the kidneys). Once seminomas have
spread beyond the limits of a radiotherapy field their management is now primarily with cisplatinum-
based chemotherapy and many centres follow the chemotherapy with radiotherapy to the initially
involved sites of disease. In contrast to the other germ cell tumours, seminomas respond to
chemotherapy and radiation by shrinkage with residual fibrosis, which can be intense. In the absence of
a surgical plane for dissection, major problems with both the aorta and the inferior vena cava have been
encountered. Since seminomas are very chemosensitive and radiosensitive, we would recommend that no
surgery is contemplated for residual masses following treatment for pure seminomas. These masses can
be followed serially on CT scans and the prognosis in this group of patients remains very good.
In patients with cell types of GCT other than seminoma, it has been shown that early cytoreductive
surgery in patients with advanced metastatic disease before chemotherapy does not improve survival
(Javadpour et al., 1982). The management of these patients is now by cisplatinum-based chemotherapy
as the initial treatment and, especially for those with large metastatic masses (greater than 5cm in the
para-aortic region), there will frequently be a residual mass visible on CT scan at the end of
chemotherapy. Our policy has been to resect any mass greater than 2cm in the para-aortic region.
Surgery here has not been a formal dissection of the para-aortic nodes but the removal of the mass
itself, which reduces the incidence of ejaculatory failure. This approach allows pathological confirmation
of the tissue in the mass. In a recent analysis of 67 patients operated on at this centre the tissue
contained fibrosis in 27%, mature teratoma in 43% and residual active malignancy in 30%. Not
surprisingly, patients who still have active tumour following chemotherapy have a poorer prognosis and
further chemotherapy is given following surgery. In particular, those with raised tumour markers before
surgery have an even worse prognosis (Jones et al., 1982; Tait et al., 1984). In general, further
chemotherapy is now given until marker-negative status is achieved before surgery is contemplated in
this latter group.
Removal of retroperitoneal masses from GCT is a specialised procedure which requires experience.
Specific problems which are encountered include the need on occasion to graft the aorta and to remove
one of the kidneys en bloc with the nodal mass. The inferior vena cava (IVC) poses a problem in that no
satisfactory graft is currently available and patients who have had IVC thrombosis develop a collateral
circulation which makes haemostasis difficult. Perhaps the worst of the complications of operating in
this area is development of a duodenal fistula, which in our experience carries a uniform mortality.
Following chemotherapy, patients may require resection for tumour masses other than in the para-
aortic region. Wedge resections of pulmonary metastases, either through a thoracotomy incision or, if
these are bilateral, through a median sternotomy, are standard procedures in selected patients. Probably
the clinical threshold for performing a thoracotomy is a residual mass of around 2cm.
Although the main subject of this editorial refers to testicular germ cell tumours, sequential
combination chemotherapy with POMB/ACE (Newlands et al., 1986) in patients with mediastinal germ
cell tumours followed by resection of the residual mass has resulted in complete remissions in all of
eight patients in our series since 1979. There is little doubt that surgery to remove residual masses
following cisplatinum-based chemotherapy does salvage some patients, and in particular those patients
with residual active tumour at the time of surgery who remain in remission. In addition, late relapses do
occur in some patients where either the residual mass is unresectable or the mass itself has been thought
small enough to be safe to leave.
Those primary GCT containing more differentiated teratomatous elements will more frequently have
residual masses at the end of chemotherapy (Oosterhuis et al., 1983). Many germ cell tumours contain
multiple cell elements and it seems likely that with current chemotherapy the most malignant elements in
the tumour (choriocarcinoma, yolk sac and embryonal carcinoma) are selectively destroyed, leaving the
teratomatous elements to differentiate into cystic masses. It should be noted that an enlarging cystic
mass on CT scan in a patient with metastatic GCT can in fact be a good prognostic feature rather than
a bad one. Clearly, surgical excision of the residual mass is necessary to confirm this.
The evolution of the management of GCT over the past decade has been dramatic. The education of
both the public and the medical profession has resulted in a much higher proportion of patients
presenting with early stage disease. The effectiveness of modern chemotherapy permits those without
metastatic disease to be watched closely without additional treatment after their orchidectomy. ThoseSURGERY AND GCT 839
patients with metastatic disease should be managed initially with cisplatinum-based chemotherapy and if
a significant residual mass persists after completing chemotherapy, this should be surgically excised
where feasible. The use of radiotherapy in GCT is now mainly in the treatment of metastatic seminoma.
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